Diabete MellitusSELECT HCLNCT07177404
Choices and Experiences Around Closed-loop Therapy in Type 1 Diabetes
An observational study of Diabete Mellitus and Type 1 Diabetes Mellitus, run by University of Nottingham at 1 site in United Kingdom.
Trial summary
Type 1 diabetes requires a lot of work to try to keep glucose levels in the target range. Hybrid closed- loop, also known as artificial pancreas, takes glucose readings from a sensor (continuous glucose monitor) and uses an algorithm to tell an insulin pump how much insulin to deliver. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabete Mellitus, Type 1 Diabetes Mellitus
- How many people
- 166 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 4 Sep 2025to 26 Feb 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Participants will be approached via their usual University Hospitals of Derby \& Burton NHS diabetes care team.
Who may be able to join
- Age: ≥18 years (no upper age limit)
- Type 1 diabetes (any duration)
- People who use closed-loop therapy or wait to start closed-loop therapy or considering closed-loop therapy in the future
- Ability to give informed consent
Who cannot join
- Any other type of diabetes apart from type 1 diabetes
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Surveying Experiences and Lifestyle Effects in Choosing Technology and Hybrid Closed Loop in Type 1 Diabetes
Type 1 diabetes requires a lot of work to try to keep glucose levels in the target range. Hybrid closed- loop, also known as artificial pancreas, takes glucose readings from a sensor (continuous glucose monitor) and uses an algorithm to tell an insulin pump how much insulin to deliver. Hybrid closed-loop has currently been rolled out to many people with type 1 diabetes in England. We are keen to develop a deeper understanding of the perspective of people living with type 1 diabetes who have choices about which hybrid closed-loop systems fit their needs.
The main purpose of this study is to explore the choices and experiences of people living with type 1 diabetes regarding closed-loop therapy.
Read the detailed description
This is a cross-sectional online survey study, which involves people with type 1 diabetes who use closed-loop, wait to start closed-loop or considering closed-loop.
The primary objective of the study is to explore the factors driving the choices of people living with type 1 diabetes regarding closed-loop therapy.
The secondary objectives of the study are:
- To understand what treatment satisfaction with closed-loop therapy means to people living with type 1 diabetes
- To understand what additional support is needed for people with type 1 diabetes using closed-loop therapy
- Conditions
- Diabete Mellitus, Type 1 Diabetes Mellitus
- Keywords
- Diabetes mellitus, Type 1 Diabetes Mellitus, Hybrid Closed Loop, Automated Insulin Delivery, Patient survey, Survey
- Medical subject headings
- Diabetes Mellitus, Diabetes Mellitus, Type 1
What is being measured
The primary outcome is the main question the study is designed to answer.
Ranking of factors influencing the choice of closed-loop therapy among people with type 1 diabetes
Measured: Day 1
Secondary outcomes (6)
Ranking of factors contributing to treatment satisfaction with closed-loop therapy
Measured: Day 1
Distribution of responses to 5-point Likert scale questions assessing factors contributing to treatment satisfaction with closed-loop therapy
Measured: Day 1
Distribution of responses to 5-point Likert scale questions assessing the support needs of people using closed-loop therapy
Measured: Day 1
Associations of demographics and reported glucose levels with factors influencing the choice of closed-loop therapy
Measured: Day 1
Associations of demographics and reported glucose levels with factors contributing to treatment satisfaction with closed-loop therapy
Measured: Day 1
Associations of demographics and reported glucose levels with support needs related to closed-loop therapy
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2025
- Study start4 Sep 2025
- Primary completion26 Feb 2026
- Study completion26 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabete MellitusStudies of the same condition, open and under way.
- More trials run by University of NottinghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 166 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07177404
- Sponsor's protocol ID
- 25026
- Acronym
- SELECT HCL
- Status last verified
- Apr 2026
- First submitted
- 1 Sep 2025
- Last updated
- 29 Apr 2026
- Results posted
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Surveying Experiences and Lifestyle Effects in Choosing Technology and Hybrid Closed Loop in Type 1 Diabetes
- ClinicalTrials.gov ID
- NCT07177404
- Acronym / sponsor ID
- SELECT HCL / 25026
- Conditions
- Diabete Mellitus, Type 1 Diabetes Mellitus
- Keywords
- Diabetes mellitus, Type 1 Diabetes Mellitus, Hybrid Closed Loop, Automated Insulin Delivery, Patient survey, Survey
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 166 participants (actual)
- Lead sponsor
- University of NottinghamUniversity, hospital or other
- Study start
- 4 Sep 2025 (actual)
- Primary completion
- 26 Feb 2026 (actual)
- Study completion
- 26 Feb 2026 (actual)
- First posted
- 17 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Type 1 diabetes requires a lot of work to try to keep glucose levels in the target range. Hybrid closed- loop, also known as artificial pancreas, takes glucose readings from a sensor (continuous glucose monitor) and uses an algorithm to tell an insulin pump how much insulin to deliver. Hybrid closed-loop has currently been rolled out to many people with type 1 diabetes in England. We are keen to develop a deeper understanding of the perspective of people living with type 1 diabetes who have choices about which hybrid closed-loop systems fit their needs.
The main purpose of this study is to explore the choices and experiences of people living with type 1 diabetes regarding closed-loop therapy.
Detailed description
This is a cross-sectional online survey study, which involves people with type 1 diabetes who use closed-loop, wait to start closed-loop or considering closed-loop.
The primary objective of the study is to explore the factors driving the choices of people living with type 1 diabetes regarding closed-loop therapy.
The secondary objectives of the study are:
- To understand what treatment satisfaction with closed-loop therapy means to people living with type 1 diabetes
- To understand what additional support is needed for people with type 1 diabetes using closed-loop therapy
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Participants will be approached via their usual University Hospitals of Derby \& Burton NHS diabetes care team.
Key inclusion criteria (4 listed)
- Age: ≥18 years (no upper age limit)
- Type 1 diabetes (any duration)
- People who use closed-loop therapy or wait to start closed-loop therapy or considering closed-loop therapy in the future
- Ability to give informed consent
Key exclusion criteria (1 listed)
- Any other type of diabetes apart from type 1 diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Ranking of factors influencing the choice of closed-loop therapy among people with type 1 diabetes
Time frame: Day 1
6 secondary outcomes
Ranking of factors contributing to treatment satisfaction with closed-loop therapy
Time frame: Day 1
Distribution of responses to 5-point Likert scale questions assessing factors contributing to treatment satisfaction with closed-loop therapy
Time frame: Day 1
Distribution of responses to 5-point Likert scale questions assessing the support needs of people using closed-loop therapy
Time frame: Day 1
Associations of demographics and reported glucose levels with factors influencing the choice of closed-loop therapy
Time frame: Day 1
Associations of demographics and reported glucose levels with factors contributing to treatment satisfaction with closed-loop therapy
Time frame: Day 1
Associations of demographics and reported glucose levels with support needs related to closed-loop therapy
Time frame: Day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Diabete Mellitus
Active, not recruitingPhase 2
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
Diabetic Kidney Disease (DKD), Type 2 Diabetes
Active, not recruitingPhase 3
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
Type 1 Diabetes
Recruiting
Culturally Tailored Program for Food-Insecure Adults: SPICE-D
Type 2 Diabetes Mellitus (T2D)
RecruitingPhase 2
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
Trauma, Hemorrhage
RecruitingObservational study
Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
Type 1 Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabete Mellitus and Type 1 Diabetes Mellitus, run by University of Nottingham at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ranking of factors influencing the choice of closed-loop therapy among people with type 1 diabetes (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.